对酒精使用障碍的治疗目标的调查:临床试验的药理学观点Trials.gov数据
1Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
International journal of general medicine
|July 10, 2025
概括
这项研究分析了对酒精使用障碍 (AUD) 的临床试验,发现重点是基于神经递质的药物和行为疗法. 新兴的治疗方法显示出希望,但需要在更大的试验中进行进一步的研究.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 酒精使用障碍 (AUD) 是一个重大的全球健康挑战,有效治疗方法有限.
- 迫切需要新的治疗策略来应对AUD的负担.
研究的目的:
- 分析注册在ClinicalTrials.gov.gov上的酒使用障碍 (AUD) 的干预性临床试验.
- 确定目前的药理和行为治疗策略,并探索AUD的新兴研究领域.
主要方法:
- 在clinicaltrials.gov的系统搜索中,发现了209个已完成的AUD干预试验.
- 试验按干预类型,药理目标,研究阶段和参与者人口统计学分类.
- 用描述性统计数据来分析研究治疗策略的特征.
主要成果:
- 药理干预主要针对神经递质系统 (胆固醇,阿片类,GABAergic,Glutamatergic) 的药理干预.
- 行为干预是常见的,通常与药物治疗相结合.
- 新兴研究探讨神经炎症和神经调节,大多数试验处于早期到中期阶段,并显示出适度的成功.
结论:
- 对AUD的临床试验主要集中在药物治疗和行为方法上.
- 针对神经免疫路径和大脑刺激的新型干预措施显示出潜力,但需要在先进的试验中进一步验证.
更多相关视频
相关概念视频
CNS Depressants: Alcohol and Nicotine
366
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
366
Drug Abuse and Addiction: Pharmacological Phenomena
659
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
659
Targets for Drug Action: Overview
7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K
Substance Use Disorders Affecting Sleep
225
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
225
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265


